Literature DB >> 1995721

A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population.

M Santosham1, G W Letson, M Wolff, R Reid, S Gahagan, R Adams, C Callahan, R B Sack, A Z Kapikian.   

Abstract

A double-blind, randomized, placebo-controlled trial was conducted to evaluate the safety and efficacy of a rhesus rotavirus vaccine and RIT 4237, a bovine rotavirus vaccine, in a Navajo population. Infants aged 2-5 months were randomized to receive one dose of either 10(4) pfu of the rhesus rotavirus vaccine or 10(8) pfu of the RIT 4237 vaccine or placebo. Eleven (10.2%) of 108 infants in the rhesus vaccine group, 11 (10.4%) of 106 in the RIT 4237 group, and 9 (8.4%) of 107 in the placebo group experienced rotavirus diarrhea during the follow-up period of 17 months. Thus, in this population, neither vaccine was efficacious in preventing rotavirus diarrhea.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995721     DOI: 10.1093/infdis/163.3.483

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Rotavirus Vaccines: Current Controversies and Future Directions.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

2.  Functional mapping of protective domains and epitopes in the rotavirus VP6 protein.

Authors:  A H Choi; M Basu; M M McNeal; J Flint; J L VanCott; J D Clements; R L Ward
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 3.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

Review 4.  Childhood immunisation today.

Authors:  J Eskola
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 5.  Performance of rotavirus vaccines in developed and developing countries.

Authors:  Victoria Jiang; Baoming Jiang; Jacqueline Tate; Umesh D Parashar; Manish M Patel
Journal:  Hum Vaccin       Date:  2010-07

6.  Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine.

Authors:  J Flores; I Perez-Schael; M Blanco; A M Rojas; E Alfonzo; I Crespo; W Cunto; A L Pittman; A Z Kapikian
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

7.  Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis.

Authors:  R H Yolken; J A Peterson; S L Vonderfecht; E T Fouts; K Midthun; D S Newburg
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

8.  Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers.

Authors:  K Y Green; A Z Kapikian
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

9.  Expression of the rotavirus SA11 protein VP7 in the simple eukaryote Dictyostelium discoideum.

Authors:  K R Emslie; J M Miller; M B Slade; P R Dormitzer; H B Greenberg; K L Williams
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Murine rotavirus genes encoding outer capsid proteins VP4 and VP7 are not major determinants of host range restriction and virulence.

Authors:  R L Broome; P T Vo; R L Ward; H F Clark; H B Greenberg
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.